Details for New Drug Application (NDA): 202313
✉ Email this page to a colleague
The generic ingredient in ADENOSINE is adenosine. There are twenty-six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adenosine profile page.
Summary for 202313
Tradename: | ADENOSINE |
Applicant: | Avet Lifesciences |
Ingredient: | adenosine |
Patents: | 0 |
Pharmacology for NDA: 202313
Mechanism of Action | Adenosine Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 202313
Suppliers and Packaging for NDA: 202313
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ADENOSINE | adenosine | SOLUTION;INTRAVENOUS | 202313 | ANDA | NorthStar Rx LLC | 16714-556 | 16714-556-01 | 1 VIAL in 1 CARTON (16714-556-01) / 20 mL in 1 VIAL |
ADENOSINE | adenosine | SOLUTION;INTRAVENOUS | 202313 | ANDA | NorthStar Rx LLC | 16714-997 | 16714-997-01 | 1 VIAL in 1 CARTON (16714-997-01) / 30 mL in 1 VIAL |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 60MG/20ML (3MG/ML) | ||||
Approval Date: | Sep 15, 2014 | TE: | AP | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 90MG/30ML (3MG/ML) | ||||
Approval Date: | Sep 15, 2014 | TE: | AP | RLD: | No |
Complete Access Available with Subscription